Comparative Pharmacology
Head-to-head clinical analysis: SALUTENSIN DEMI versus TRIBENZOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SALUTENSIN DEMI versus TRIBENZOR.
SALUTENSIN-DEMI vs TRIBENZOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Salutensin-Demi is a combination of hydroflumethiazide, a thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption, and reserpine, an adrenergic neuron-blocking agent that depletes catecholamines from peripheral nerve endings, reducing sympathetic outflow.
TRIBENZOR is a fixed-dose combination of olmesartan, an angiotensin II receptor blocker that inhibits the vasopressor and aldosterone-secreting effects of angiotensin II, and amlodipine, a dihydropyridine calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in vasodilation.
1 tablet (15 mg hydrochlorothiazide + 0.075 mg clonidine) orally once daily, with titration based on blood pressure response.
Tribenzor (olmesartan medoxomil/amlodipine/hydrochlorothiazide) is available in fixed-dose combinations. Typical adult dose: one tablet orally once daily. Starting dose depends on prior antihypertensive therapy; maximum recommended dose is olmesartan 40 mg/amlodipine 10 mg/HCTZ 25 mg per day.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hours (terminal), clinical effect lasts 6-12 hours; Reserpine: 50-100 hours (terminal), with prolonged action due to irreversible vesicular depletion
Terminal half-life 9-11 hours; supports once-daily dosing
Renal: hydrochlorothiazide 70% unchanged, reserpine <1% unchanged; fecal: reserpine ~6% as metabolites
Renal: 50-60% as unchanged drug and metabolites; Biliary/Fecal: 40-50%
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination